Avidity Biosciences, Inc. (NASDAQ: RNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $67.00 price target on the stock.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025